Finally, in a third 2023 statement, 15 IBD experts from 13 countries agreed that anti-TNF-α biosimilars can be used both in biologic-naïve patients and those already treated with the reference medicine; transitioning from a reference anti-TNF-α biologic to a biosimilar counterpart can be performed at any time; and switching to biosimilar anti-TNF-α agents is a way to reduce the costs associated with advanced therapies and to increase treatment accessibility [50]. The gene discussed is TNF; the disease is inflammatory bowel disease.